These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
452 related articles for article (PubMed ID: 21573959)
41. Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement. Porta C; Tortora G; Linassier C; Papazisis K; Awada A; Berthold D; Maroto JP; Powles T; De Santis M Med Oncol; 2012 Sep; 29(3):1896-907. PubMed ID: 21735145 [TBL] [Abstract][Full Text] [Related]
42. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach. Bukowski RM Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712 [TBL] [Abstract][Full Text] [Related]
43. Evolving role of novel targeted agents in renal cell carcinoma. Hutson TE; Figlin RA Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797 [TBL] [Abstract][Full Text] [Related]
44. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. Agarwala SS; Case S Oncologist; 2010; 15(3):236-45. PubMed ID: 20215359 [TBL] [Abstract][Full Text] [Related]
45. Sunitinib malate for the treatment of renal cell carcinoma. Wood L Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009 [TBL] [Abstract][Full Text] [Related]
47. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma. Zivi A; Cerbone L; Recine F; Sternberg CN Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374 [TBL] [Abstract][Full Text] [Related]
48. Patterns of Care in Patients with Metastatic Renal Cell Carcinoma Among a U.S. Payer Population with Commercial or Medicare Advantage Membership. Miller LA; Stemkowski S; Saverno K; Lane DC; Tao Z; Hackshaw MD; Loy B J Manag Care Spec Pharm; 2016 Mar; 22(3):219-26. PubMed ID: 27003551 [TBL] [Abstract][Full Text] [Related]
49. Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. Paule B; Bastien L; Deslandes E; Cussenot O; Podgorniak MP; Allory Y; Naïmi B; Porcher R; de La Taille A; Menashi S; Calvo F; Mourah S PLoS One; 2010 May; 5(5):e10715. PubMed ID: 20502715 [TBL] [Abstract][Full Text] [Related]
50. Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence. Tonini G; Fratto ME; Imperatori M; Pantano F; Vincenzi B; Santini D Expert Rev Anticancer Ther; 2011 Jun; 11(6):921-30. PubMed ID: 21707289 [TBL] [Abstract][Full Text] [Related]
51. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors. Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453 [TBL] [Abstract][Full Text] [Related]
52. Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines. Martin B; Edeline J; Patard JJ; Oger E; Jouan F; Boulanger G; Zerrouki S; Vigneau C; Rioux-Leclercq N J Cancer Res Clin Oncol; 2012 Jun; 138(6):907-16. PubMed ID: 22322364 [TBL] [Abstract][Full Text] [Related]
53. Targeted therapy in renal cell carcinoma. Patard JJ; Pouessel D; Bensalah K; Culine S World J Urol; 2008 Apr; 26(2):135-40. PubMed ID: 18265991 [TBL] [Abstract][Full Text] [Related]
54. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Ravaud A Oncologist; 2011; 16 Suppl 2(Suppl 2):32-44. PubMed ID: 21346038 [TBL] [Abstract][Full Text] [Related]
55. First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis. Rousseau B; Kempf E; Desamericq G; Boissier E; Chaubet-Houdu M; Joly C; Saldana C; Boussion H; Neuzillet C; Macquin-Mavier I; Oudard S; Salomon L; de la Taille A; Tournigand C Crit Rev Oncol Hematol; 2016 Nov; 107():44-53. PubMed ID: 27823651 [TBL] [Abstract][Full Text] [Related]
56. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461 [TBL] [Abstract][Full Text] [Related]